Laboratory Corporation of America Holdings (LH) : The total money flow in Laboratory Corporation of America Holdings (LH) was negative ($4.74 million), which signals selling by the traders on Mondays session. They trimmed their holdings by selling the stock on downticks to the tune of $18.59 million. In comparison, the inflow of money into the stock on upticks was $13.86 million. The uptick to downtick ratio was 0.75. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $10.68 million. The value of transactions on uptick was $6.81 million. The negative money flow of ($3.87 million) confirms the selling in Laboratory Corporation of America Holdings (LH) on strength. The uptick to downtick ratio of block trades was 0.64. Laboratory Corporation of America Holdings (LH) gained $0.26 at $136.45, a gain of 0.19% over the previous days close. However, the stock registered 0.85% in the week.
Laboratory Corp. of America Holdings is up 14.81% in the last 3-month period. Year-to-Date the stock performance stands at 10.34%. Shares of Laboratory Corp. of America Holdings rose by 0.64% in the last five trading days and 7.12% for the last 4 weeks. In a related news,The director officer (President & CEO) of Laboratory Corp Of America Holdings, King David P sold 196,400 shares at $128.42 on June 13, 2016. The Insider selling transaction had a total value worth of $25,221,688. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Laboratory Corporation of America Holdings (NYSE:LH): stock turned positive on Monday. Though the stock opened at $136.12, the bulls momentum made the stock top out at $136.97 level for the day. The stock recorded a low of $135.67 and closed the trading day at $136.42, in the green by 0.17%. The total traded volume for the day was 500,501. The stock had closed at $136.19 in the previous days trading.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.